Introduction {#S1}
============

Best characterized in studies of brewer's yeast, macroautophagy (hereafter referred to as autophagy) is a degradative process for long-lived proteins and damaged organelles ([@B64]). In neurons, autophagy is considered to play both protective and pathogenic roles, as it contributes not only to proteostasis and cell survival ([@B29]; [@B44]; [@B103]; [@B104]), but also to autophagic cell death in neurodegenerative diseases ([@B28]; [@B99]; [@B12]; [@B108]; [@B106]). Recently, autophagy has been recognized as an important cellular process during neuronal development ([@B82]; [@B89]; [@B19]; [@B87]; [@B41]; [@B54]). Autophagic dysfunction is observed in humans with neurodevelopmental disorders ([@B50]; [@B69]; [@B9]; [@B33]), and mouse models with reduced autophagy display phenotypes implicated in autism spectrum disorders (ASD) ([@B89]; [@B41]; [@B107]). Importantly, autophagic dysfunction is found in both genetic and environmental animal models of ASD, suggesting its impairment may be a general feature of ASD pathophysiology ([@B89]; [@B70]; [@B110], [@B111]; [@B102]; [@B107]). Notably, rodents prenatally exposed to valproic acid (VPA) show a reduction in brain autophagy accompanied by a series of morphological alterations and behavioral impairments consistent with the ASD symptomatology described in patients ([@B70]; [@B110]; [@B102]; [@B111]). Yet, little is known about the developmental regulation of neuronal autophagy and the possible implications for ASD.

Recently, the striatum, which is the main input nucleus of the basal ganglia, a brain circuit controlling action selection and reward processing, has been implicated in the pathophysiology of multiple neurodevelopmental diseases including ASD ([@B26]; [@B25]). Moreover, the principal neurons of the striatum, the spiny projection neurons (SPNs), although they migrate to the striatum during the embryonic period ([@B86]), undergo a significant maturation during the first four postnatal weeks. SPNs receive excitatory inputs from the cortex and thalamus during the second and third postnatal weeks ([@B91]). Dopaminergic axons innervate the striatum at birth but their ability to release neurotransmitter increases during the first 2 weeks ([@B98]; [@B53]). Finally, the intrinsic excitability of SPNs matures from weeks two through four ([@B91]; [@B66]). Notably, autophagy has been proposed to contribute to synaptic maturation and plasticity and dopamine release ([@B32]; [@B89]; [@B63]). Thus, establishing whether autophagy is differentially regulated during postnatal development of the striatum and determining whether this temporal regulation is impaired in ASD would provide insights into its role in neurodevelopmental disorders.

Autophagy is a tightly regulated multi-step process ([@B5]) that, in dividing cells is controlled by energy balance (i.e., nutrient status) and metabolic kinases, including the mammalian target of rapamycin (mTOR). mTOR regulates autophagy via several mechanisms ([@B30]), including by phosphorylating and negatively regulating Unc-51-like autophagy-activating kinase 1 (ULK1) at Ser757 ([@B38]; [@B42]). This step prevents ULK1-mediated phosphorylation of Beclin-1 at Ser14, and the subsequent increase of PI3K activity of Vps34 ([@B75]). These molecular events initiate the formation of preautophagic structures that are subsequently expanded by a molecular cascade resulting in the modification of LC3, one of the mammalian homologs of the yeast Atg8 ([@B84]). Processing of LC3 leads to phagophore expansion and sealing and is used as a biochemical readout of autophagosome formation ([@B39]; [@B43]). The enclosed, mature autophagosome then traffics to the lysosome where the autophagic cargo and cargo adaptors, such as p62, are degraded ([@B90]).

Whether similar signaling regulates autophagy in neurons remains controversial. It has been proposed that autophagy may act as a constitutive process for cellular homeostasis, thus circumventing the control of metabolic kinases such as mTOR ([@B106]). The links between nutrient status and autophagy in neurons moreover remain elusive, with reports suggesting a regional and age-specific autophagic response to nutrient deprivation in neurons ([@B40]; [@B63]) and studies indicating the contrary ([@B60]). Moreover, direct regulation of autophagy by mTOR, independent of nutrient status, has been reported by some ([@B32]; [@B89]) but not others ([@B97]; [@B56]). These contrasting results raise important questions concerning the control of autophagic activity in brain regions implicated in neurodevelopmental diseases, the molecular changes associated with pathologic conditions and the nature of signaling pathways that regulate autophagy in neurons (i.e., signaling operating during nutrient deprivation-induced autophagy in non-neuronal cells).

Using biochemical, pharmacological and histological approaches, we first demonstrate that in SPNs autophagy is dynamically downregulated during postnatal development, following the upregulation of mTOR activity. Then we employ the VPA model of ASD which has construct, face and predictive validity ([@B13]; [@B73]; [@B62]) to show that in the striatum of ASD model mice, autophagy is specifically reduced during a discrete developmental window (P28). At the same postnatal age, we also observe changes in excitatory synaptic transmission. Finally, we find that mice exposed to VPA *in utero* display a social deficit and that systemic treatment with rapamycin, an inhibitor of mTOR, normalizes it. Our results suggest that autophagy may play temporally-specific roles in brain postnatal development and that it may be one of the pathogenic signaling pathways implicated in neurodevelopmental disorders and ASD.

Results {#S2}
=======

Markers of Autophagic Activity Decrease During Striatal Postnatal Development {#S2.SS1}
-----------------------------------------------------------------------------

To identify changes in autophagic activity during postnatal striatal development, we collected striata from mice at postnatal days 10, 14, 18, 28 and in adults (postnatal day 120; [@B91]; [@B66]; [@B53]). These postnatal ages represent critical timepoints for striatal development. Briefly, synaptic dopamine release has begun and interneurons have begun to mature in the striatum at postnatal day 10 ([@B68]; [@B22]; [@B53]). By postnatal day 14, excitatory inputs from the cortex and thalamus arrive and eye opening has occurred, providing higher levels of sensory input. P18 represents the end of synaptogenesis and an age immediately before weaning. At age P28, the period of postnatal refinement has ended ([@B91]). We compared tissue from these ages to mice in early adulthood at postnatal day 120.

We first measured the levels of DARPP32, a classic SPN marker, and actin as a loading control across postnatal development and found no differences ([Figure 1A](#F1){ref-type="fig"}). We then measured the level of total and processed form of the Atg8 family member, LC3B ([@B90]; [@B43]). We found a significant effect of age on the levels of processed LC3B (LC3B-ii) relative to actin and unprocessed LC3B (LC3B-i) ([Figures 1A--C](#F1){ref-type="fig"}). The level of the autophagic adapter protein, p62, whose steady-state levels are determined by its own autophagic degradation, increased over the postnatal period ([Figure 1D](#F1){ref-type="fig"}). These data suggest that overall autophagic activity decreases during the first four postnatal weeks.

![Autophagy decreases during striatal development. **(A)** Representative Western blot images for LC3B, p62, DARPP32, and actin. Quantification of **(B)** LC3B-ii relative to actin, **(C)** LC3B-ii relative to LC3B-i, **(D)** p62 relative to actin normalized to P120 values. Data analyzed with one-way ANOVA; **(B)** Age: *F*~(4~,~21)~ = 6.526, *p* = 0.0014; **(C)** Age: *F*~(4~,~22)~ = 3.797, *p* = 0.0171; **(D)** Age: *F*~(4~,~15)~ = 3.762, *p* = 0.0260. \**p* \< 0.05, \*\**p* \< 0.01, *n* = 4--6 mice/age. **(E,F)** Representative images of DARPP32 stained striatal neurons and RFP fluorescence from mice aged P10 and P28. Dashed lines indicate cell body outlines. **(G)** Quantification of number of LC3 puncta/cell. Unpaired, two-tailed *t*-test, *t*~4~ = 4.392, *p* = 0.0118. *N* = 3 mice/age, 20--50 cells were analyzed per mouse.](fncel-14-00070-g001){#F1}

LC3 + Puncta Decrease in Striatal Spiny Projection Neurons During Postnatal Development {#S2.SS2}
---------------------------------------------------------------------------------------

Western blot analysis of total striatal lysates includes proteins from all cell types present in the striatum, including neurons, glia, and vascular cells. To define the cell type in which the developmental changes in autophagy occur, we utilized a transgenic mouse ubiquitously expressing LC3 fused to both green (GFP) and red fluorescent proteins (RFPs) ([Supplementary Figure S1A](#FS1){ref-type="supplementary-material"}; tandem fluorescent-tagged LC3 or tfLC3) ([@B51]). After processing, LC3 transitions from the cytosol to become membrane-bound on the autophagosome (LC3B-ii). Visualizing the distribution of fluorophore-tagged LC3 (LC3 puncta) provides a well-established assay for monitoring autophagic activity within a cell ([@B43]). Furthermore, as the fluorescence of the GFP component is quenched by the low pH of the lysosome, tfLC3 permits analysis of the total number of autophagosomes and autolysosomes (RFP + puncta) and non-acidified autophagosomes (GFP + RFP + puncta).

We first used 2-photon microscopy to simultaneously image GFP and RFP signals in acute brain slices tfLC3 mice at age P10 and P28 ([Supplementary Figures S1B,C](#FS1){ref-type="supplementary-material"}). At both ages, GFP fluorescence was diffuse in the cytosol and processes of striatal cells and RFP + puncta were present in the soma. The density of the striatal neuropil prevented analysis of tfLC3 + puncta in axons or dendrites ([Supplementary Figures S1B,C](#FS1){ref-type="supplementary-material"}). Because the level of GFP fluorescence was too strong in the soma to discern individual puncta, we used the number of RFP puncta as a proxy for autophagosomes, with the caveat that we were unable to determine whether these puncta were also fused with lysosomes.

To identify the number of RFP + puncta in specific cell types, we perfused mice at age P10 and P28 and co-labeled with cell-type specific markers of striatal neurons. Spiny projection neurons can be identified by immunostaining with antibodies against DARPP-32. We observed a significant decrease in RFP + puncta in DARPP32 + cells between P10 and P28 ([Figures 1E--G](#F1){ref-type="fig"}), indicating that the reduction in autophagic activity occurs in SPNs. To determine whether autophagy is similarly regulated in other striatal cells, we quantified the number of RFP + puncta in DARPP32- cells. We did not find a significant difference in the number of RPF + puncta in DARRP32- cells between P10 and P28 (P10 = 15 ± 3.14 and P28 = 22.43 ± 4.12; Unpaired, two-tailed *t*-test, ns; *N* = 3 mice/age). These results suggest that the reduction in autophagic activity we measured using biochemical assays of striatal lysates occurs specifically in SPNs.

Autophagosome Biosynthesis Is Suppressed During Postnatal Development {#S2.SS3}
---------------------------------------------------------------------

Changes in the level of LC3B-ii, or the number of LC3 puncta, can arise from increases in autophagosome biosynthesis or decreases in the efficiency of autophagosome maturation and lysosomal degradation. To dissect the changes in autophagy during the postnatal period, we developed an *ex vivo* system to test the effects of drugs that do not cross the blood-brain barrier ([Figure 2A](#F2){ref-type="fig"}). We generated acute brain slices from P10 or P28 mice and removed non-striatal tissue. We found that neither the slice procedure nor the incubation affected the age-dependent reduction in autophagy markers observed *in vivo* ([Figures 2A,B](#F2){ref-type="fig"} compared to [Figure 1](#F1){ref-type="fig"}). This confirms that the mechanisms underlying changes in autophagic markers during postnatal development can be defined using this *ex vivo* system.

![Striatal autophagic flux decreases from P10 to P28. **(A)** Schematic of coronal brain section showing dissection boundaries for *ex vivo* experiments. **(B)** Quantification of LC3B-ii relative to actin for every vehicle-only slice showed in [Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}. Unpaired, two-tailed *t*-test, *t*~52~ = 5.824, \*\*\*\**p* \< 0.0001. **(C)** Representative Western blot images of actin, DARPP32 and LC3B in slices obtained from P10 or P28 mice, incubated with BafA1 (100 nM, 3 h) or vehicle (Veh; DMSO, 0.1%). **(D)** LC3B-ii relative to actin, normalized to vehicle condition at each age. P10: unpaired, two-tailed *t*-test, *t*~25~ = 5.113, \*\*\*\**p* \< 0.0001; P28: unpaired, two-tailed *t*-test, *t*~10~ = 0.6228, *p* = 0.5473. P10: Veh: *n* = 16 slices, BafA1 *n* = 11 slices from 4 to 6 mice. P28: Veh: *n* = 6 slices, BafA1 *n* = 6 slices from three mice.](fncel-14-00070-g002){#F2}

We incubated slices from mice at age P10 and P28 with bafilomycin A1 (BafA1, 100 nM), a specific inhibitor of the vacuolar proton pump, or vehicle (DMSO, 0.1%) for 3 h, an incubation time similar to that used in cultured cells ([@B43]), to prevent lysosomal acidification and block autophagosome-lysosome fusion. As treatment with BafA1 prevents LC3B-ii degradation, changes in LC3B-ii levels following BafA1 treatment are interpreted as the rate of autophagosome biosynthesis. BafA1 treatment increased LC3B-ii in slices from P10 mice but, had no significant effect in slices from P28 mice ([Figures 2C,D](#F2){ref-type="fig"}). BafA1 treatment had no effect on DARPP32 levels at either age ([Figure 2C](#F2){ref-type="fig"}). Slices from either age treated with BafA1 for 1 h showed no change in LC3B-ii levels (data not shown). This suggests that the higher baseline level of LC3B-ii at P10 arises from increased autophagosome biosynthesis.

mTOR Signaling Is Upregulated During the Postnatal Development {#S2.SS4}
--------------------------------------------------------------

mTOR signaling is a key negative regulator of autophagic activity. We therefore hypothesized that mTOR activity in the striatum increases during postnatal development and suppresses autophagy.

mTOR kinase activity can be monitored by measuring the state of phosphorylation of its downstream targets. The level of phosphorylation at serine 757 of ULK1, which is phosphorylated by mTOR and inhibits ULK1 kinase activity ([@B42]), increased during the postnatal period in the striatum ([Figures 3A--C](#F3){ref-type="fig"}). We then confirmed that ULK1 kinase activity is inhibited by monitoring the phosphorylation state of Beclin-1, a ULK1 target. Phosphorylation of Beclin-1 at serine 14 decreased during postnatal development ([Figures 3A--C](#F3){ref-type="fig"}). mTOR activity also leads to the indirect phosphorylation of the ribosomal protein S6 (rpS6) on serine 240 and serine 244, via activation of the S6 kinase 1 \[S6K1; [Figure 3A](#F3){ref-type="fig"} ([@B57])\]. We observed a sharp increase in rpS6 Ser240/244 at P18 before decreasing into adulthood ([Figures 3B,D](#F3){ref-type="fig"}). Overall these data indicate an increase in mTOR activity during striatal postnatal development. Interestingly, we did not observe a significant effect of age on phosphorylation of ERK1/2 ([Figures 3B,D](#F3){ref-type="fig"}) suggesting that increased mTOR activity during the postnatal period is not associated with a global change in molecular signaling.

![mTOR signaling increases during striatal development. **(A)** Schematic representation of mTOR targets. mTOR inhibits ULK1 activity by phosphorylating Ser757. P-ULK1 activates Vps34 activity (not shown) by phosphorylating Beclin-1 on Ser14. mTOR promotes protein synthesis by activation of S6K-1 (not shown), which phosphorylates rpS6 on Ser240/244. The single and double arrows indicate direct (i.e., ULK1, Beclin-1) and indirect (i.e., rpS6) downstream targets, respectively. **(B)** Representative Western blot images quantified in **(C,D)**. **(C)** Quantification of pULK1 S757 relative to actin (gray squares) and p-Beclin S14 relative to total Beclin-1 (black dots). Data analyzed with one-way ANOVA; p-ULK1 S757/actin: age: *F*~(4~,~13)~ = 6.093, *p* = 0.0055; p-Beclin-1S14/total Beclin-1: age: *F*~(4~,~14)~ = 4.945, *p* = 0.0107. **(D)** Quantification of p-rpS6 S240/244 and p-Erk1/2 relative to total rpS6 and total Erk1/2, respectively. Data analyzed with one-way ANOVA; p-rpS6 240/244: age: *F*~(4~,~20)~ = 12.69, *p* \< 0.0001. p-Erk1: age: *F*~(4~,~17)~ = 2.625, *p* = 0.0712. p-Erk2: age: *F*~(4~,~17)~ = 0.3561, *p* = 0.8362. *N* = 3--6 mice/age. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\*\**p* \< 0.0001.](fncel-14-00070-g003){#F3}

mTOR and vps34 Regulate LC3B-ii Levels During Striatal Postnatal Development {#S2.SS5}
----------------------------------------------------------------------------

mTOR negatively regulates autophagosome biosynthesis by inhibiting ULK1 activity ([@B38]; [@B42]). When ULK1 is active, it promotes autophagosome formation by phosphorylating Beclin-1, which increases the PI3K activity of its partner, Vps34 ([@B75]). To address whether elevated autophagy at P10 was a result of enhanced Vps34 activity, we incubated acute striatal slices with the Vps34 inhibitor, SAR405 (1 μM) or vehicle (DMSO, 0.1%) for 3 h ([@B72]). SAR405 significantly reduced the level of LC3B-ii in slices from mice at age P10 but had no effect on slices from P28 mice ([Figures 4A--C](#F4){ref-type="fig"}). This demonstrates that elevated autophagic activity in the striatum of early postnatal mice is Vps34-dependent. The lack of effect of SAR405 on autophagic activity at P28 indicates that reduced Vps34 activity, possibly via increased mTOR signaling ([Figure 3](#F3){ref-type="fig"}), is responsible for the lower levels of autophagic flux at P28. As predicted SAR405 does not change the levels of phosphorylated Beclin-1 at P10 (veh: 100 ± 9.433 and SAR405: 103.2 ± 6.982; Unpaired, two-tailed *t*-test, ns. *n* = 4 slices/3 mice) and P28 (veh: 100 ± 11.89 and SAR405: 85.29 ± 6.813; Unpaired, two-tailed *t*-test, ns. *n* = 5 slices/3 mice), indicating that there are no regulatory loops altering the activation of Beclin-1 in response to inhibition of Vsp34 activity.

![Vps34 activity is required for maintaining LC3B-ii levels at P10 and mTOR inhibition increases p-Beclin-1 and LC3B-ii levels at P28. **(A)** Representative Western blot images for actin, DARPP32 and LC3B-i and -ii in striatal slices obtained from P10 or P28 mice, treated with SAR405 (1 μM) or vehicle (Veh; DMSO, 0.1%). **(B,C)** Quantification of LC3B-ii relative to actin, normalized to vehicle condition at each age. **(B)** P10: unpaired, two-tailed *t*-test, *t*~11~ = 2.985, *p* = 0.0124; P28: unpaired, two-tailed *t*-test, *t*~24~ = 1.807, *p* = 0.0922. P10: Veh: *n* = 6 slices, SAR405 *n* = 7 slices from 3 to 4 mice/age. **(C)** P28: Veh: *n* = 9 slices, Baf *n* = 7 slices from 3 to 4 mice/age. \**p* \< 0.05. **(D)** Representative Western blot images for actin, DARPP32, p-Beclin-1 Ser14 and LC3B-i and -ii in striatal slices from P28 mice, treated with Torin-1 (5 μM) or vehicle (Veh; DMSO, 0.1%). Quantification of **(E)** LC3B-ii and **(F)** p-Beclin S14 relative to actin, normalized to vehicle. Data analyzed with unpaired, two-tailed *t*-test; **(E)** LC3B-ii/actin, *t*~24~ = 2.853, *p* = 0.0088. Veh: *n* = 19 slices, Baf *n* = 7 slices from 5 to 7 mice. \**p* \< 0.05. **(F)** p-Beclin S14/actin, *t*~22~ = 3.337, *p* = 0.0030. \*\**p* \< 0.01, Veh: *n* = 18 slices, Torin-1 *n* = 6 slices from 3 to 5 mice.](fncel-14-00070-g004){#F4}

Having shown that Vps34 drives elevated autophagy at P10, we explored whether enhanced mTOR activity inhibits autophagy at P28. mTOR activity can be pharmacologically inhibited by direct active site inhibitors, such as Torin-1 ([@B94]). We incubated striatal slices from mice at P28 with Torin-1 (5 μM) or vehicle (DMSO, 0.1%) for 3 h and measured LC3B-ii levels. Torin-1 treatment increased LC3B-ii levels and the phosphorylation of Beclin-1 at the ULK1 site (Ser14), suggesting that mTOR inhibition activates autophagy in a ULK1/Beclin-1 dependent manner ([Figures 4D--F](#F4){ref-type="fig"}).

Prenatal VPA Exposure Determine a Decrease in Autophagy During the Late Postnatal Period {#S2.SS6}
----------------------------------------------------------------------------------------

To gain insights into the involvement of autophagy in neurodevelopmental disorders and ASD, we asked whether autophagic markers are dysregulated during the postnatal striatal development in the VPA mouse model of ASD.

We examined the effects of prenatal VPA exposure \[600 mg/kg administered subcutaneously to pregnant mothers at gestational day 12 ([@B73])\] on autophagy by collecting the striata of vehicle (Veh) or VPA-treated (VPA) mice at P10 and P28 ([Figure 5A](#F5){ref-type="fig"}). Interestingly, we found a significant elevation in phosphorylation of rpS6 at Ser240/244 at P28 but not at P10 in VPA-treated mice compared to vehicle ([Figures 5B--D](#F5){ref-type="fig"}), suggesting that mTOR signaling was increased following *in utero* VPA exposure. In agreement, we observed a significant decrease in LC3B-ii and an increase of p62 at P28 but not at P10 in VPA-treated mice compared to vehicle ([Figures 5B,E--H](#F5){ref-type="fig"}). We verified that we enriched for striatal tissue in all groups by probing for DARPP-32 ([Figures 5B,I,J](#F5){ref-type="fig"}). Overall, these data suggest that prenatal VPA exposure affects mTOR signaling and autophagy only during the late striatal postnatal development (P28).

![VPA reduces autophagy at P28. **(A)** Schematic of VPA administration. **(B)** Representative Western blot images for LC3B, p62, p-rpS6 S240/244, DARPP32, and actin. **(B--G)** Quantification of **(B--D)** p-rpS6 S240/244 relative to actin, **(B,E,F)** LC3B-ii relative to actin **(B,G,H)** p62 and **(B,I,J)** DARPP32 normalized to VPA untreated (veh, vehicle) mice at P10 and P28, respectively. Data analyzed with unpaired, two-tailed *t*-test; **(C)** p-rpS6 S240/244/actin at P10, ns; **(D)** p-rpS6 S240/244/actin at P28, *t*~11~ = 2.882, *p* = 0.0149 **(E)** LC3B-ii/actin at P10, ns; **(F)** LC3B-ii/actin at P28, *t*~10~ = 2.231, *p* = 0.047; **(G)** p62 at P10, ns; **(H)** p62 at P28, *t*~10~ = 3.752, *p* = 0.0038; **(I)** DARPP32 at P10, ns, and **(J)** DARPP32 at P10, ns, \**p* \< 0.05, \*\**p* \< 0.01, ns not significant, *n* = 4--7 mice/treatment.](fncel-14-00070-g005){#F5}

Prenatal VPA Exposure Induces Impairments in SPNs Synaptic Transmission {#S2.SS7}
-----------------------------------------------------------------------

Because autophagy is important for synaptic function ([@B32]; [@B89]; [@B63]) and prenatal VPA exposure affects synaptic transmission in the hippocampus and cortex ([@B73]), we determined whether the reduction in autophagy induced by VPA at P28 was also accompanied by a functional change in striatal synaptic transmission.

To this end we prepared acute brain slices from P28 veh- and VPA-treated mice and recorded excitatory and inhibitory synaptic transmission in SPNs. In VPA-treated mice, we discovered a decrease in the frequency and increase in the amplitude of mEPSCs compared to vehicle treated mice ([Figures 6A--C](#F6){ref-type="fig"}). In contrast, prenatal exposure to VPA did not affect mIPSC frequency or amplitude at P28 ([Figures 6D--F](#F6){ref-type="fig"}). This data suggest that impaired excitatory transmission occurs in SPNs of mice prenatally exposed to VPA.

![*In utero* VPA exposure impairs striatal excitatory synaptic transmission at P28. **(A)** Representative voltage-clamp recordings of mEPSCs from SPNs in Veh or VPA treated mice. **(B)** Reduction in mEPSC frequency in VPA-treated mice. Veh: *N* = 19 cells, VPA: *N* = 21 cells. *t*~38~ = 2.246, *p* = 0.0306. **(C)** Increased in mEPSC amplitude in VPA-treated mice. Veh: *N* = 19 cells, VPA: *N* = 21 cells. *t*~38~ = 2.113, *p* = 0.0412. **(D)** Representative voltage-clamp recordings of mIPSCs from SPNs in Veh or VPA-treated mice. No difference in mIPSC **(E)** frequency or **(F)** amplitude. Veh: *N* = 10 cells, VPA: *N* = 19 cells. \**p* \< 0.05, ns not significant.](fncel-14-00070-g006){#F6}

Prenatal VPA Exposure Induces Alteration in Social Behavior That Is Normalized by Treatment With Rapamycin {#S2.SS8}
----------------------------------------------------------------------------------------------------------

Since repetitive behaviors and social impairments are required for ASD diagnosis \[[@B17]\] and are present in genetic models of ASD ([@B46]; [@B21]; [@B112]; [@B95], [@B96]; [@B27]; [@B77]; [@B35]) and VPA-treated rats ([@B10]), we asked whether prenatal exposure to VPA could result in altered repetitive and social behaviors.

We utilized the marble burying test to determine the presence of repetitive behaviors in VPA-exposed or control mice ([@B92], [@B93]; [@B31]; [@B85]; [@B34]). In this test, the mice are free to explore a cage with 20 marbles arranged in a grid on the surface of the bedding. After 20 min of exploration, we counted the marbles that were buried by the mice. We did not find a significant difference in the number of marbles buried by control and VPA-exposed mice (vehicle-treated mice = 12.86 ± 1.1, VPA-treated mice = 12.57 ± 1.288. Unpaired, two-tailed *t*-test, ns. *N* = 7 mice/treatment). This result suggests that the onset of the repetitive behaviors occurs later than P28 for VPA-exposed mice.

We utilized the three chamber social arena to assess social behavior in VPA-exposed or control mice ([@B61]). After a period of habituation (10 min) to the arena, the mice are free to interact for another 10 min with another conspecific mouse (stranger) or with an object confined inside wire cups in the right and left chambers of the arena ([Figure 7A](#F7){ref-type="fig"}). We found that VPA exposed mice spent significantly less time interacting with the social cue as compared to vehicle exposed mice ([Figure 7B](#F7){ref-type="fig"}).

![*In utero* exposure to VPA reduces social approach behavior which is rescued by mTOR inhibition**. (A)** Schematic of three chamber arena. Subjects are placed in the center chamber and allowed to explore for 10 min. After this, a conspecific mouse (stranger) is placed in one side chamber and an object is placed in the other side chamber. The subject is allowed to explore the entire arena for 10 min and time spent interacting with either the conspecific (stranger) or the object is recorded. **(B)** The interaction time with stranger and object for control (Veh) and VPA-exposed mice (VPA). Two-way repeated measures ANOVA: treatment x chamber *F*~(1~,~12)~ = 30.48, \*\*\*\**p* \< 0.0001. **(C)** Rapamycin treated Veh and VPA exposed mice show no difference in interaction time with the stranger. Two-way repeated measures ANOVA: treatment x chamber *F*~(1~,~12)~ = 0.1397, *p* = 0.7151. Treatment: *F*~(1~,~12)~ = 1.584, *p* = 0.2321. Chamber: *F*~(1~,~12)~ = 89.93, *p* \< 0.0001. **(D,E)** No difference in locomotor activity between Veh and VPA-exposed mice at baseline or following rapamycin treatment. **(D)** unpaired, two-tailed *t*-test, *t*~12~ = 0.3940, *p* = 0.7005. **(E)** Unpaired, two-tailed *t*-test, *t*~12~ = 0.4253, *p* = 0.6781.](fncel-14-00070-g007){#F7}

Since we found that VPA-exposed mice displayed an impairment in social behavior, We also investigated whether inhibiting mTOR activity with rapamycin would result in a normalization of the social abnormalities as described in genetic models of ASD ([@B112]; [@B95], [@B96]; [@B89]). Rapamycin crosses the blood brain barrier, it has been extensively used *in vivo* to inhibit the activity of mTOR in the multiprotein complex 1 (mTORC1) and, rescue ASD-like behaviors ([@B112]; [@B95], [@B96]; [@B89]). We treated VPA-exposed and control mice with rapamycin (5 mg/kg; injected intraperitoneally (i.p.) once a day) for 4 days, a treatment that was previously showed to be effective in blocking mTOR in the brain ([@B21]; [@B76]; [@B34]). On the fifth day, 1 h after the rapamycin injection, we subjected the mice to the three chamber arena test. Rapamycin normalized the behavior of VPA-exposed mice. Thus, after rapamycin treatment, the interaction time displayed by vehicle and VPA-treated mice is similar ([Figure 7C](#F7){ref-type="fig"}).

Finally, one possible explanation for the social behavior displayed by VPA-exposed mice (at baseline and following rapamycin treatment) is a change in total locomotor activity. We quantified the total locomotor activity of the mice in the three chamber arena and we found no difference between groups ([Figures 7D,E](#F7){ref-type="fig"}), suggesting that the changes in the interaction time with the social cue are not caused by alteration in exploratory behavior.

Discussion {#S3}
==========

Neuronal autophagy has been proposed to play a key role in neurodevelopment and autophagic dysfunction may lead to neurodevelopmental disorders and ASD ([@B89]; [@B19]; [@B41]; [@B107]; [@B55]). In this study we address whether autophagic activity is developmentally controlled in the principal neurons of the striatum, a brain region implicated in neurodevelopmental disorders ([@B25]). We found that autophagy is dynamically regulated in SPNs during postnatal development, reaching adult levels around P28. These findings provide mechanistic insight into the regulation of autophagy during striatal postnatal development and establish the basis for a further evaluation of its role in physiological and pathological conditions.

The involvement of the striatum in ASD pathophysiology have been suggested by clinical and experimental observations ([@B25]). Magnetic resonance imaging (MRI) and functional-MRI studies indicate anatomical and task-specific alterations in the striatum of ASD patients ([@B79]; [@B47], [@B48]; [@B80]; [@B16]). Moreover, environmental and genetic animal models of ASD have contributed to conclusively demonstrate a causal relationship between striatal functions and pathophysiological alterations ASD-like ([@B1]; [@B11]; [@B80]; [@B83]; [@B65]; [@B67]; [@B18]; [@B77]). Interestingly, we have recently discovered that autophagy is differentially involved in the control of the synaptic functions and excitability of the two subtypes of SPNs (i.e., direct and indirect SPNs; [@B52]). Moreover, mice with specific genetic deletion of atg7, a protein required for autophagy, either in direct or indirect SPNs display hyperactivity, stereotypes and behavioral abnormalities consistent with ASD ([@B52]). Given the dynamic regulations of autophagy occurring in the SPNs during postnatal development and the ASD-like phenotypes displayed by mice with genetic ablation of autophagy in SPNs, the regulation of autophagy during early postnatal development of SPNs may be one of the cellular process disrupted in ASD.

By analyzing key endogenous biochemical markers (such as LC3B-ii, p62, p-Ser757-ULK1, and p-Ser14-Beclin-1), we discovered that autophagy decreases progressively during the postnatal development of SPNs. The autophagy markers were measured in bulk lysates containing neurons, glia and endothelial cells (among others). To identify the cell types that feature changes during postnatal development, we utilized tfLC3 mice ([@B51]). Given the challenges in assaying endogenous autophagic proteins using immunofluorescence, tfLC3 mice provide a unique resource, as overexpressed LC3 is fused to fluorescent proteins that permit morphological characterization of autophagic structure. While the high levels of expression prevented the identification of individual autophagic puncta in both live imaging ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}) and fixed tissue (not shown), the level of autophagolysosomes represented by RFP-LC3 + puncta was higher in SPN somata at P10 than at P28, in agreement with our biochemical analysis ([Figure 1](#F1){ref-type="fig"}).

Autophagic flux is determined by the kinetics of autophagosome biosynthesis, autophagosome maturation and autophagic cargo degradation by lysosomal proteases. Steady-state measurement of LC3B-ii levels provide a useful proxy for the measurement of autophagic activity. An elevated level of LC3B-ii could indicate either increased or decreased autophagic flux, as both increased autophagosome biosynthesis *and* decreased lysosomal degradation of autophagic proteins can increase LC3B-ii ([@B39]; [@B43]). To functionally measure autophagic flux in striatal tissue, we developed an *ex vivo* acute brain slice system and found that steady state increases in LC3B-ii levels at P10 were further elevated by acute blockade of lysosomal degradation with BafA1 compared to LC3B-ii levels at P28. This suggests that increased autophagic flux is responsible for the higher steady-state LC3B-ii levels, as inhibition of lysosomal degradation would not have an effect on LC3B-ii levels if lysosomal degradation were already compromised. These results indicate that the postnatal suppression of autophagy results from changes in autophagosome biosynthesis or maturation.

In line with changes in autophagosome biosynthesis/maturation during striatal development, we found that mTOR-dependent signaling increases over the course of postnatal development, thereby suppressing autophagosome synthesis via inhibition of ULK1 and Beclin-1 activity. These include downstream targets involved in protein synthesis, such as rpS6, and autophagy, such as ULK1. In this regard, it is interesting to note that the phosphorylation state of rpS6 follows a slightly different pattern than ULK-1 during postnatal development. One of the reasons of this discrepancy may be the different phosphorylation kinetic of activated mTOR on the rpS6, which is an indirect target regulated via S6K-1 ([@B57]), and on ULK-1, which is a direct target ([@B42]). Alternatively, a reduction in phosphorylated rpS6 may be the result of the enhanced activity of protein phosphatase 1 (PP1), which dephosphorylates rpS6 ([@B4]). It has been showed that the phosphorylation of rpS6 in SPNs is determined by the suppression of dephosphorylation via PKA/DARPP-32-mediated inhibition of PP1 ([@B7]). Thus, it is possible that a reduction in PKA/DARPP-32 results in an increased PP1 activity which, in turn dephosphorylates rpS6. Finally, a reduction of phosphorylated rpS6 may also be achieved by increased activity of PP2A-like phosphatases, which dephosphorylate and reduce the activation of S6K-1 ([@B57]).

mTOR specifically phosphorylates ULK1 at Ser757 and inhibits its kinase activity ([@B42]). Consistently, we also observed a decrease in the level of phosphorylation on the ULK1 site in Beclin-1, a key component of the class III-PI3K complex required for autophagosome biosynthesis ([@B36]; [@B75]). These results provide a functional readout for increased mTOR activity on autophagy-specific downstream targets and demonstrate a direct link between mTOR signaling and a regulation of autophagy activity observed during the postnatal development. Inhibition of mTOR activity at P28, when mTOR activity is elevated, induces autophagy and increases the phosphorylation of Beclin-1 at Ser14 and LC3B-ii levels. Further work will also focus on whether additional kinases which integrate metabolic status in the periphery, such as AMPK ([@B30]), control developmental changes in neuronal autophagy.

These findings may help to resolve conflicting results present in the literature. Several groups have found that mTOR inhibition fails to increase autophagic activity in primary neuronal culture ([@B97]; [@B56]) or *in vivo* ([@B23]). In contrast, others report that pharmacological ([@B32]; [@B89]) or genetic inhibition of mTOR drives autophagy ([@B107]) as well as hyperactivation of mTOR signaling inhibits autophagy in the CNS ([@B58]; [@B89]; [@B20]). This discrepancy may arise from model system used (i.e., cell culture vs. *in vivo*), developmental stage, or treatment paradigm. Defining the substrates that mTOR acts on during brain development is critically important given recent approvals of mTOR inhibitors in neurodevelopmental disease ([@B24]; [@B15]). Our findings suggest that mTOR signaling is important for the regulation of autophagy during critical developmental windows in neurons in a manner unrelated to nutrient status. mTOR signaling is under the control of several neural-specific signals such as patterned neuronal activity and specific neurotransmitters or neuromodulators ([@B109]; [@B76]; [@B2]; [@B6]; [@B88]), suggesting possible mechanisms through which mTOR activity is regulated within developing neural circuits. There is a broad range of significant changes in neurotransmitter content, neuronal firing patterns and synaptic plasticity that occurs during this period, providing a plethora of candidates that could dynamically regulate mTOR signaling and autophagy during the course of postnatal development. Autophagy is also known to regulate surface levels of neurotransmitter receptors, axon pathfinding, synaptic maturation and plasticity, suggesting that autophagy acts dynamically during early postnatal developmental to entrain adult-like neuronal activity that subsequently suppresses autophagy by activating mTOR signaling ([@B74]; [@B32]; [@B81]; [@B89]; [@B19]; [@B63]). Such a feedback process may provide a temporal and mechanistic framework for future studies that address the role of autophagy, and its regulation by mTOR, in neuronal development.

The VPA animal model of ASD, a non-genetic model extensively used to study the neurobiology of ASD and to test for novel behavioral and pharmacological treatments thank to its face, construct and predictive validity ([@B13]; [@B73]; [@B62]). Prenatal exposure to VPA in humans is associated with neural tube defects and other congenital malformations ([@B37]; [@B101]), neurocognitive impairments, including low IQ ([@B59]) and high risk of ASD ([@B8]; [@B14]). Similarly, in rodents, VPA induces a robust range of ASD-like behavioral and morphological alterations (reviewed in [@B13]; [@B73]; [@B62]). Adult rodents exposed to VPA display a reduction of brain autophagy in associations with the behavioral and morphological alterations ([@B70]; [@B110], [@B111]; [@B102]). In line with these results, we found altered autophagic markers, such as decreased LC3B-ii and increased p62, in the striatum of P28 mice prenatally exposed to VPA. Moreover, we discover that at P10 the VPA does not significantly change autophagy. Thus, it seems that prenatal exposure to VPA determines a detectable reduction of striatal autophagy only during the late postnatal development (P28) that it is maintained in the adulthood ([@B70]; [@B110], [@B111]; [@B102]). The lack of detectable change in autophagy at P10 may be the result of the high autophagic flux that masks the impairment in autophagy. Alternatively, it may be due to an ongoing accumulation of autophagic markers that are under detectable threshold at those early time points.

Consistent with our data demonstrating a direct link between dynamic change in mTOR activity and autophagy during postnatal development of SPNs, we found an increased phosphorylation of rpS6 in VPA treated animals at P28. This result suggests that autophagy and protein synthesis are concomitantly dysregulated through aberrant mTOR activity.

Impaired protein synthesis and autophagy have also been described in genetic ASD animal models ([@B3]) and the presence of similar changes also in the non-genetic VPA model may indicate that these represent pathogenic signaling pathways underlying ASD. This molecular characterization may be of importance for early detection and therapeutic treatment of ASD.

We also discovered that reduction of autophagy in VPA-treated mice is accompanied by changes in synaptic transmission at P28. We found a decrease in frequency and increase in amplitude of mEPSCs, which may indicate a reduction in the number of spines and an increase in the strength of the synaptic connection in the striatum of mice prenatally exposed to VPA. This synaptic phenotype is in line with a previous publication reporting a reduction of corticostriatal synapses in the rostral striatum of VPA treated mice ([@B45]). Moreover, decreased mEPSCs frequency in VPA treated mice is also present in the cerebellar cortex ([@B100]). Reduction in excitatory striatal inputs is also observed in genetic mouse models of ASD ([@B25]).

Finally, we found that mice exposed prenatally to VPA display altered social interaction in the three chamber arena test. This is similar to what is observed in rats treated with VPA ([@B10]). Systemic treatment with rapamycin (5 mg/kg/day, injected i.p. for 5 days) normalizes the social impairments of VPA treated mice. We are aware of the fact that rapamycin will likely affect all the molecular pathways regulated by mTOR, including protein synthesis which is an important signaling cascade involved in ASD ([@B34]). Moreover, the systemic administration of rapamycin leads to an inhibition of mTOR not only in the striatum but also in other brain regions regulating social behaviors. Further studies with more specific autophagy inhibitors administered locally or with genetic manipulation of autophagic regulators restricted to the striatum are needed to conclusively demonstrate the involvement of striatal autophagy in the generation of social deficits in the VPA animal model.

In summary, we find that the postnatal development of SPNs is correlated with a change in autophagy and this is determined by mTOR signaling status. We also find that in ASD model mice, mTOR-dependent autophagy is downregulated in SPNs and it is accompanied by impairments in synaptic transmission and social behavior in the late postnatal development.

Materials and Methods {#S4}
=====================

Animals {#S4.SS1}
-------

Breeder pairs of C57/BL6J were obtained from Jackson Laboratories (Bar Harbor, ME, United States). Mice were checked every day or every other day for pregnancy and new litters. TfLC3 mice were obtained from Jackson Laboratories \[C57BL/6-Tg(CAG-RFP/EGFP/Map1lc3b)1Hill/J; Strain No. 027139\]. Breeder pairs were housed on a 12-h light/dark cycle with water and food available *ad libitum*. Offspring were weaned between postnatal day 18 and 20 and split into same sex groups of 2--5. Mice of both sexes were utilized for experiments in [Figures 1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"} and data were combined as no effect of gender was observed.

For the VPA experiments, pregnant female breeders received a single subcutaneous injection of VPA at the dose of 600 mg/kg during gestational day 12 ([@B49]; [@B45]; [@B100]). Control pregnant females received an equivalent dose of vehicle at gestational day 12. Only male mice of the offspring were utilized for these experiments (in [Figures 5](#F5){ref-type="fig"}--[7](#F7){ref-type="fig"}) ([@B49]; [@B45]; [@B100]).

All experimental procedures were approved by the Columbia University Institutional Animal Care and Use Committee and was conducted in accordance with animal care guidelines of National Institute of Health.

*In vivo* Sample Preparation {#S4.SS2}
----------------------------

Striatal sample preparation was performed as previously described ([@B78]). Mice at specified ages were rapidly decapitated and their head was briefly placed in liquid nitrogen. The brain was subsequently removed and a single striatum was dissected and flash frozen in liquid nitrogen. Samples were stored at −80°C until the full cohort was collected. Samples were then homogenized in 1% SDS by a brief sonication. Protein content was determined by the BCA assay (Thermo Fisher). No significant effect of age was found on total protein (data not shown). Samples were then boiled in sample buffer and frozen until western blot analysis.

Acute Brain Slice {#S4.SS3}
-----------------

Acute brain slices were prepared essentially as described ([@B53]). Briefly, mice underwent cervical dislocation and the brain was removed and placed in ice-cold high sucrose cutting solution (in mM): 10 NaCl, 2.5 KCl, 25 NaHCO~3~, 0.5 CaCl~2~, 7 MgCl~2~, 1.25 NaH~2~PO~4~, 180 sucrose, 10 glucose bubbled with 95% O~2~/5% CO~2~ to pH 7.4. Brains were mounted on a VT1200 vibratome (Leica Biosystems) and coronal sections (250 μm) including the striatum were collected. For the biochemistry experiments, slices were then transferred to a basin contained ice-cold cutting solution and the striatum was manually dissected. Slices were moved to scintillation vials containing 7 mL of ACSF (in mM): 125 NaCl, 2.5 KCl, 25 NaHCO~3~, 2 CaCl~2~, 1 MgCl~2~, 1.25 NaH~2~PO~4~, and 10 glucose bubbled with 95% O~2~/5% CO~2~ to pH 7.4 at 34°C. Slices from two mice at the same age were combined in individual experiments and split into four conditions. Slices were allowed to rest for 1 h followed by addition of vehicle or drug. Following incubation with drug at 34°C for the specified time, slices were removed and flash frozen in liquid nitrogen. After slices were collected from a complete experiment (i.e., slices from 4 to 6 mice per age, at P10 and P28), slices were homogenized by sonication in 1% SDS and prepared as described above for Western blot analysis.

Patch-Clamp Electrophysiology {#S4.SS4}
-----------------------------

Recording pipettes were fabricated from borosilicate glass microcapillaries and had resistances of 4--6 MΩ when filled with internal solution (see below). Putative SPNs were visualized in corticostriatal slices with a SliceScope (Scientifica, United Kingdom) equipped with a 40 × 0.8 NA water-immersion objective (LUMPlanFLN, Olympus, United States) and Dodt contrast tube optics. Data were recorded with a MultiClamp 700B amplifier (Molecular Devices, United States), low-pass filtered at 5 kHz and digitized at 10 kHz with a digidata 1550b to a personal computer running pClamp 11 (Molecular Devices). Cell capacitance and series resistance (\<25 MOhm) were left uncompensated but were monitored by applying a hyperpolarizing voltage-command (5 mV) at regular intervals. Recordings where series resistance increased above 25 MOhm were discarded.

Whole cell patch-clamp recordings of miniature excitatory and inhibitory synaptic currents (mEPSCs, mIPSCs, "minis") were performed at −70 mV holding potential, in the presence of tetrodotoxin (TTX, 0.5 μM) and picrotoxin (100 μM, mEPSCs) or kynurenic acid (1 mM, mIPSCs). For mEPSCs the recording pipette contained (in mM): [K]{.smallcaps}-gluconate, 120; KCl, 20; EGTA, 0.1; HEPES, 10; Na~2~-phosphocreatine, 5; Na~2~ATP, 4; Na~2~GTP, 0.3, adjusted to pH 7.25 with KOH (300 mOsm/l), and for mIPSCs the pipettes contained (in mM): KCl, 140; HEPES, 10; EGTA, 1; Na~2~ATP, 2; Na~2~GTP 0.2; pH 7.25. Recordings were performed at 32--34°C (TC324C, Warner Instruments, United States).

The cells were filled with recording solution for at least 10 min and data was collected during 3 min. The amplitude and frequency of the minis were analyzed off-line using Clampfit 10.7. Traces were filtered at 1 kHz and synaptic events were detected using the event detection function and template search. The amplitude and frequency from each recording were averaged and group comparisons were performed between slices using unpaired *t*-test assuming equal variances. The number of mice were \> 4 per group.

Western Blot {#S4.SS5}
------------

Equivalent amount of protein per sample (5--25 μg/well) were loaded into 10, 12, or 4--12% gradient polyacrylamide gels as described ([@B78]). Protein was transferred from the gel to an Immobilon FL PVDF membrane (pore size 0.2 μm). Blots were blocked in TBS with 0.1% Tween-20 (TBST) and 5% fat-free, dry milk for 1 h at room temperature. Blots were then incubated with primary antibody (see [Table 1](#T1){ref-type="table"} for detailed information regarding antibodies) diluted in TBST with 5% BSA as specified (see [Table 1](#T1){ref-type="table"} for dilution and antibody sources) overnight at 4°C. Blots were then washed with TBST and incubated in secondary antibody for 1 h at room temperature. Blots were developed using either the Odyssey imaging system (LICOR) or an enhanced chemiluminescence (ECL) system (Amersham) and imaged using an Azure Biosystems C600 system. Western blots developed using the Odyssey system were analyzed in Image Studio Lite (LICOR). Western blots developed with the ECL system were analyzed using standard routines in ImageJ. All samples were probed for beta-actin and DARPP32 as loading and dissection controls, respectively.

###### 

Antibodies.

  Antibody                                            Company (Catalog No.)               Dilution        Detection method   Notes
  --------------------------------------------------- ----------------------------------- --------------- ------------------ -----------------------------------
  Rabbit anti LC3B                                    Novus Biologicals (NB600-1384)      1:1000          Odyssey            12% SDS-PAGE gel required
  Rabbit anti p62                                     MBL (PM045)                         1:1000          Odyssey            Atg7KO validated (data not shown)
  Rabbit anti Darpp32                                 Cell Signaling Technology (2306)    1:2500--5000    Odyssey            
  Mouse anti β-Actin                                  Novus Biologicals (NB600-501)       1:5000--10000   Odyssey            
  Rabbit anti p-ULK1 (Ser757)                         Cell Signaling Technology (6888)    1:500           Odyssey            
  Rabbit anti Beclin                                  Cell Signaling Technology (3495)    1:1000          ECL                
  Rabbit anti p-Beclin-1 (Ser14)                      Cell Signaling Technology (84966)   1:1000          ECL                
  Rabbit anti S6 ribosomal protein                    Cell Signaling Technology (2217)    1:1000--2000    ECL                
  Rabbit anti p-S6 ribosomal protein (Ser240/244)     Cell Signaling Technology (2215)    1:1000--2000    ECL                
  Rabbit anti p44/42 MAPK (Erk1/2)                    Cell Signaling Technology (4695)    1:1000          Odyssey            
  Rabbit anti p-p44/42 MAPK (Erk1/2; Thr202/Tyr204)   Cell Signaling Technology (4370)    1:1000          Odyssey            

Drugs and Chemicals {#S4.SS6}
-------------------

Sodium valproate (VPA) was purchased from ACROS Organics, dissolved in saline solution and administered subcutaneously to pregnant females at the dose of 600 mg/kg. BafA1 and Torin-1 were purchased from Tocris. SAR 405 was purchased from Cayman Chemicals. Unless otherwise stated, all drugs were dissolved in DMSO and slices were incubated in ACSF containing the drugs or equivalent volume of vehicles for 3 h at 34°C. DMSO did not exceed a final concentration of 0.1%. All other chemicals were purchased from Fisher Scientific.

Bafilomycin A1 was used at a concentration of 100 nM, a concentration that effectively blocks autophagolysosome fusion in primary neuronal culture and in transformed cell lines ([@B105]; [@B56]; [@B71]). SAR405 was used at 1 μM in acute brain slice experiments. This concentration showed both maximal efficacy in inhibiting autophagy and no off target effects in cell culture experiments ([@B72]). Torin-1 was used at 5 μM. Rapamycin, another mTOR inhibitor is generally used at concentrations between 1 and 5 μM in both cell culture and in acute brain slice; however, Torin-1 has an IC50 of mTORC1 activity about 5X greater than the IC50 of rapamycin ([@B94]). Therefore, we used 5 μM and confirmed that this inhibited rpS6 phosphorylation and mTOR activity in the acute brain slice.

Rapamycin (LC Laboratories) was dissolved in 1% DMSO and 5% Tween-80 in saline and injected i.p. at the dose of 5 mg/kg (vehicle treated mice received an equivalent dose of vehicle). Rapamycin (5 mg/kg) was injected i.p. once a day for 5 days. On the last day of the treatment, the mice were subjected to the three chamber sociability test (see below) 1 h after the injection. This regimen was chosen because it generates brain rapamycin concentrations in a range previously established to inhibit mTOR and normalize ASD-like behaviors and behaviors dependent on mTOR activation ([@B21]; [@B112]; [@B34]; [@B96]).

2p-Microscopy {#S4.SS7}
-------------

Two-photon images were acquired on a Prairie Ultima microscope system (Middleton, WI, United States) using PrairieView 4.3 software. Acute brain slices were transferred into a chamber and perfused with oxygenated ACSF at room temperature. Samples were excited with a Coherent (Santa Clara, CA, United States) Chameleon Ultra two-photon laser at 980 nm, and images were simultaneously collected through two photomultiplier tube channels with corresponding 585--630 and 490--560 nm emission windows. The objective used was a 60X, 0.9 NA water immersion lens, and images were 1024 × 1024 pixels in size.

Immunohistochemistry {#S4.SS8}
--------------------

Mice were deeply anesthestized and transcardially perfused with 0.9% NaCl followed by 4% paraformaldehyde (PFA) in 0.1M phosphate buffer (PB). Brains were removed and post-fixed overnight in 4% PFA in 0.1M PB. Brains were then washed three times in 1X phosphate buffered saline and cut into 40 μm sections using a VT1200 vibratome (Leica Biosystems) and stored in cryoprotectant (0.1M PB, 30% glycerol, 30% ethylene glycol) at −20°C. For immunofluorescence analysis, sections were washed in TBS three times and then blocked and permeabilized for 1 h at room temperature with 10% normal donkey serum (Jackson Immunoresearch) and 0.1% Triton-X in TBS. Sections were then incubated overnight at 4°C with primary antibodies in 2% normal donkey serum, 0.1% Triton-X in TBS. Primary antibodies included: Rabbit anti-DARPP32 (Cell Signaling), and Chicken anti-Green Fluorescent Protein (Abcam). Secondary antibodies with the appropriate conjugated fluorphores were purchased from Invitrogen. The endogenous fluorescence of RFP was imaged. Sections were then washed in TBS and mounted. Images were obtained using a Leica SP5 confocal system with argon, DPSS He/Ne lasers. Images were obtained with a 63X oil immersion objective with a 2X digital zoom at 2048 × 2048 resolution (∼120 nm resolution). All images were taken with the same laser intensity and detector settings with non-saturating pixel intensities.

Image analysis was conducted in ImageJ. Cell bodies were segmented using DARPP32 stained (DARPP32+) and not stained (DARPP32−) cells. RFP + puncta within each segment was counted manually. 10--20 cells were counted per section, 2--4 sections were counted per animal. Average number of puncta per cell was determined from *n* = 3 animals per age. All images were collected, and all analyses were conducted blind to condition.

Marble Burying Test {#S4.SS9}
-------------------

Marble burying was measured as previously described ([@B1]; [@B11]; [@B80]; [@B83]; [@B65]; [@B67]; [@B18]; [@B77]). Briefly, 20 glass marbles (around 15 mm in diameter) were arranged in a symmetrical (4 × 5) grid on the surface of 2--3 cm deep bedding in clean, standard mouse cages with transparent wall extensions (20 cm) to avoid climbing or jumping of mice. Each mouse was placed in the center of the cage for a 20-min exploration period, after which the number of marbles buried was tallied by investigators blind to the treatment. 'Buried' was defined as \> 50% covered by bedding according to [@B92]. Testing was performed under dim light (∼15 lux) and recorded with a videocamera.

Three Chamber Sociability Test {#S4.SS10}
------------------------------

Social behavior was measured using a 3-chambered social arena as described previously ([@B61]). Briefly, mice received a 10 min habituation session to the arena in the presence of two wire cages, one in each side of the chamber. A 10 min social preference test followed in which the mice were allowed to explore the arena containing a wired cage with a conspecific mouse (stranger mouse) or a wire cage with an inanimate object in the two lateral chambers. The placement of social and non-social targets was counterbalanced between animals. The measured parameters of social interaction and locomotor activity were the interaction time (sec) with each target (during the social preference test session) and the total distance (cm) moved (during habituation and social preference test sessions) respectively, calculated by Ethovision XT video tracking software (Noldus).

Statistical Analysis {#S4.SS11}
--------------------

All analysis was conducted blind to condition. For statistical analysis between two groups, unpaired, two-tailed *t*-tests were used. For analysis between three or more groups, one-way ANOVA was used. Sociability test was analyzed with two-way repeated measure ANOVA (within factors: treatment and social cue), followed by multiple comparisons using Bonferroni's test. Normality was not formally tested. Sample size was not based on a formal power analysis but was based on past work from our groups and similar experiments from the literature. Statistical analysis was conducted in GraphPad Prism 7 (La Jolla, CA, United States). All bar graphs show the mean ± SEM.

Data Availability Statement {#S5}
===========================

The datasets generated for this study are available on request to the corresponding author.

Ethics Statement {#S6}
================

The animal study was reviewed and approved by Columbia University Institutional Animal Care and Use Committee.

Author Contributions {#S7}
====================

OL and ES: conception. OL, MP, AB, and ES: methodology. OL, IP, VC, MM, MB, MP, JC, AB, and ES: investigation. OL: writing -- original draft and visualization. OL, IP, MP, DS, AB, and ES: writing -- review and editing. ES: supervision. DS and ES: funding acquisition.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** OL was supported by NIH T32 GM007367 and NIH F30 MH114390, VC by The Foundation Blanceflor Boncompagni Ludovisi, née Bildt, MP by NIH 5T32MH020004, DS by NIH R01 DA007418 and the Simons and JPB Foundations, AB by Swedish Research Council (2016-03129), Magnus Bergvall Foundation, Åhlens Stiftelse, The Karolinska Institute Strategic Research Program in Neuroscience (StratNeuro) and ES by NIH R00 NS087112, Swedish Research Council (2016-02758), The Knut and Alice Wallenberg Academy Fellowship, The Olle Engkvist Byggmästare Foundation, The Karolinska Institute StratNeuro and The Karolinska Institute Internal Fund.

We thank Ai Yamamoto for insightful discussions about the manuscript; Dritan Agalliu for generously sharing the LICOR Odyssey system; and Gilberto Fisone for critical reading of the manuscript. This manuscript has been released as a Pre-Print at bioRxiv.

Supplementary Material {#S10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fncel.2020.00070/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: João Peça, University of Coimbra, Portugal

[^2]: Reviewed by: Chan Young Shin, Konkuk University, South Korea; Junyu Xu, Zhejiang University, China

[^3]: This article was submitted to Cellular Neuropathology, a section of the journal Frontiers in Cellular Neuroscience
